Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure

被引:0
|
作者
Gutovitz, Joel [1 ]
Kutcher, Jonathan [1 ]
Cherney, David Z. [2 ]
Schiller, Yael [1 ]
Gabizon, Itzhak [3 ]
Keshet, Eran [4 ]
Rimon, Jordan [4 ]
Koren, David [5 ]
Rao, Vivek [6 ]
Grosman-Rimon, Liza [7 ]
机构
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON, Canada
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Cardiol, Beer Sheva, Israel
[4] York Univ, Fac Hlth, Toronto, ON, Canada
[5] Sheba Med Ctr, Dept Cardiac Surg, Tel Hashomer, Israel
[6] Univ Hlth Network, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[7] Acad Coll Levinsky Wingate, Wingate Inst, IL-6937808 Netanya, Israel
关键词
end-stage heart failure; inflammation; systolic ejection time; CARDIAC MYOSIN ACTIVATOR; CHEMOKINES; RECEPTORS;
D O I
10.14423/SMJ.0000000000001801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesSystolic ejection time (SET) and systemic inflammation are two essential indicators of heart failure (HF) progression. We aimed to evaluate the associations between SET and inflammatory mediators in end-stage HF. MethodsParticipants included 16 patients with end-stage HF recruited from the Heart Failure Clinic at Toronto General Hospital and 16 healthy individuals free of any known cardiovascular disease. SET, end systolic pressure, and levels of inflammatory mediators were documented for each patient, and a Spearman rank correlation coefficient was performed to examine differences between patients with end-stage HF and healthy controls. ResultsThe mean SET in patients with HF was shorter than in the healthy controls (283.5 +/- 34.3 ms vs 330.1 +/- 19.0 ms, P < 0.001). C-reactive protein (P = 0.001), macrophage inflammatory protein-1 beta (P = 0.041), macrophage-derived chemokine (P = 0.007), and cyclic guanosine monophosphate (P < 0.001) levels were negatively correlated with SET. The levels of other inflammatory mediators-granulocyte-stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin-8, macrophage inflammatory protein-1, macrophage inflammatory protein-1 alpha, and tumor necrosis factor alpha-were not significantly correlated with SET. ConclusionsWe found that SET was significantly lower in patients with end-stage HF compared with healthy controls and that reduced SET correlated with increased levels of several inflammatory mediators in patients with HF. By better understanding the relationship between SET and inflammation in HF, a more thorough evaluation could lead to improved risk stratification among patients with HF. Future work should investigate the roles of SET and inflammation in HF.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 50 条
  • [31] End-stage heart failure: which options?
    Deng, MC
    Ascheim, DD
    Edwards, NM
    Naka, Y
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2002, 4 (0D) : D122 - D130
  • [32] Advanced Therapies For End-Stage Heart Failure
    Katz, Jason N.
    Waters, Sarah B.
    Hollis, Ian B.
    Chang, Patricia P.
    CURRENT CARDIOLOGY REVIEWS, 2015, 11 (01) : 63 - 72
  • [33] Surgical approach to end-stage heart failure
    Klotz, Stefan
    Scheld, Hans H.
    CURRENT OPINION IN ANESTHESIOLOGY, 2011, 24 (01) : 86 - 91
  • [34] Obesity in patients with end-stage heart failure
    Krol, Bogumila
    Oprzedkiewicz, Aleksandra
    Szczurek, Wioletta
    Szygula-Jurkiewicz, Bozena
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2018, 15 (03): : 176 - 179
  • [35] Sympathetic Activity in Patients With Secondary Symptomatic Mitral Regurgitation or End-Stage Systolic Heart Failure
    Ozturk, Can
    Schueler, Robert
    Weber, Marcel
    Welz, Armin
    Werner, Nikos
    Nickenig, Georg
    Hammerstingl, Christoph
    JACC-CARDIOVASCULAR INTERVENTIONS, 2016, 9 (19) : 2050 - 2057
  • [36] Serum Protein Levels as Biomarkers of Muscle Strength in Patients with End-Stage Systolic Heart Failure
    Karanja, P. W.
    Singla, A.
    Chery, J.
    Coston, A.
    Vest, A. R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S215 - S215
  • [37] CLINICAL PROFILING OF END-STAGE HEART FAILURE WITH PRESERVED EJECTION FRACTION: THE NATIONAL READMISSION DATABASE
    Mohebi, Reza
    Liu, Yuxi
    Murphy, Sean P.
    Gaggin, Hanna Kim
    Januzzi, James L., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 634 - 634
  • [38] Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
    Mohebi, Reza
    Liu, Yuxi
    Murphy, Sean P.
    Gaggin, Hanna K.
    Januzzi Jr, James L.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 378 : 71 - 76
  • [39] Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease
    Inampudi, Chakradhari
    Alvarez, Paulino
    Asleh, Rabea
    Briasoulis, Alexandros
    CURRENT CARDIOLOGY REVIEWS, 2018, 14 (01) : 60 - 66
  • [40] Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease
    Lee, Seonhwa
    Oh, Jaewon
    Kim, Hyoeun
    Ha, Jaehyung
    Chun, Kyeong-hyeon
    Lee, Chan Joo
    Park, Sungha
    Lee, Sang-Hak
    Kang, Seok-Min
    ESC HEART FAILURE, 2020, 7 (03): : 1125 - 1129